Euro-Med Laboratories PhilippinesPHS:EURO 84 EBITDA Margin % is 14.99% as of Mar. 2026, which is 19% below its 10-year median of 18.50. GuruFocus rates PHS:EURO with a GF Score™ of 84/100 and a GF Value™ of ₱1.02 (Fairly Valued). The stock has 6 warning signs investors should review. Among 955 Drug Manufacturers companies, Euro-Med Laboratories Philippines ranks better than 66.39% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Euro-Med Laboratories Philippines EBITDA Margin % Related Terms
Euro-Med Laboratories Philippines EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PHS:EURO vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Euro-Med Laboratories Philippines's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Euro-Med Laboratories Philippines EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Euro-Med Laboratories Philippines's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Euro-Med Laboratories Philippines's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Euro-Med Laboratories Philippines (PHS:EURO) has a EBITDA Margin % of 14.99% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Euro-Med Laboratories Philippines and its competitors. This is 19% below median its historical median of 18.50. Over the past decade, Euro-Med Laboratories Philippines' EBITDA Margin % has ranged from 17.60 to 20.55. According to the industry distribution chart, Euro-Med Laboratories Philippines ranks #321 out of 955 companies in the Drug Manufacturers industry, placing it in the top 33.6%.
Is Euro-Med Laboratories Philippines' EBITDA Margin % too high?
Euro-Med Laboratories Philippines' current EBITDA Margin % of 14.99% is 19% below median its 10-year median of 18.50. Over the past 10 years, this metric has ranged from a low of 17.60 to a high of 20.55. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Euro-Med Laboratories Philippines' value of 14.99% is 20.5% above this industry median. Based on the distribution chart, Euro-Med Laboratories Philippines ranks #321 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Euro-Med Laboratories Philippines has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Euro-Med Laboratories Philippines' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Euro-Med Laboratories Philippines ranks #321 out of 955 companies for EBITDA Margin %. This puts Euro-Med Laboratories Philippines in the upper half of its industry. The industry median EBITDA Margin % is 12.44. Euro-Med Laboratories Philippines' value of 14.99% is 20.5% above this benchmark. Historically, Euro-Med Laboratories Philippines' own EBITDA Margin % has ranged from 17.60 to 20.55 over the past decade. While the company's 10-year median is 18.50 vs. the industry median of 12.44, Euro-Med Laboratories Philippines has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Euro-Med Laboratories Philippines's current EBITDA Margin % of 14.99% is 20.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Euro-Med Laboratories Philippines and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Euro-Med Laboratories Philippines's current EBITDA Margin % is 14.99%, which is 19% below median its own 10-year median of 18.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Euro-Med Laboratories Philippines stock overvalued right now?
Based on GuruFocus' analysis, Euro-Med Laboratories Philippines (PHS:EURO) is currently considered Fairly Valued. The stock's GF Value™ is ₱1.02, compared to a current price of ₱1.08 — trading 5.9% above its estimated fair value. The current EBITDA Margin % is 14.99%, which is 19% below median its 10-year median of 18.50 and 20.5% above the Drug Manufacturers industry median of 12.44. Euro-Med Laboratories Philippines' overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Euro-Med Laboratories Philippines (PHS:EURO), the current EBITDA Margin % is 14.99% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Euro-Med Laboratories Philippines (PHS:EURO) Overvalued in 2026?
Based on GuruFocus' analysis, Euro-Med Laboratories Philippines stock appears to be overvalued.
The current stock price of ₱1.08 is trading 5.9% above its estimated GF Value™ of ₱1.02.
GuruFocus considers Euro-Med Laboratories Philippines to be Fairly Valued.
Key valuation signals for PHS:EURO:
EBITDA Margin %: 14.99% (19% below median its 10-year median of 18.50)
GF Value™: ₱1.02 vs. price of ₱1.08 (5.9% above fair value)
Industry Position: 20.5% above the Drug Manufacturers median (#321 of 955)
No single metric tells the full story. See the PHS:EURO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Euro-Med Laboratories Philippines Business Description
Euro-Med Laboratories Philippines Inc is a pharmaceutical-based company that engages in the manufacture of pharmaceutical products such as large and small-volume parenterals and other solutions. The company also manufactures sterile water for injection, and other solutions such as ophthalmic, inhalation, irrigation, and dialysis. The Company also manufactures intravenous fluids in glass bottles, hemodialysis concentrates, ophthalmic products and disinfectants.
84GF Score
Get the complete analysis for PHS:EURO
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHS:EURO has been successfully added to your 
